SRR8943039
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.350
- FATTY_ACID_METABOLISM+0.340
- CHOLESTEROL_HOMEOSTASIS+0.330
- SPERMATOGENESIS+0.250
- PANCREAS_BETA_CELLS+0.230
- XENOBIOTIC_METABOLISM+0.230
- ESTROGEN_RESPONSE_LATE+0.210
- MYOGENESIS+0.210
- BILE_ACID_METABOLISM+0.200
- APICAL_SURFACE+0.160
Top 10 suppressed
- TGF_BETA_SIGNALING-0.460
- NOTCH_SIGNALING-0.400
- WNT_BETA_CATENIN_SIGNALING-0.390
- TNFA_SIGNALING_VIA_NFKB-0.330
- ALLOGRAFT_REJECTION-0.320
- INFLAMMATORY_RESPONSE-0.290
- P53_PATHWAY-0.290
- PI3K_AKT_MTOR_SIGNALING-0.280
- IL6_JAK_STAT3_SIGNALING-0.260
- UV_RESPONSE_DN-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A8HC-01A-11R-A36F-07 | — | — | 0.769 |
| 2 | MNG1129 | — | — | 0.748 |
| 3 | SRR23303742 | — | — | 0.738 |
| 4 | ERR2208929 | — | — | 0.736 |
| 5 | SRR13780262 | — | cohortSC | 0.733 |
| 6 | GSM5359431 | — | — | 0.720 |
| 7 | TCGA-NK-A7XE-01A-12R-A405-07 | — | cohortSQ1 | 0.712 |
| 8 | DRR168528 | — | — | 0.712 |
| 9 | R219 | — | — | 0.709 |
| 10 | SRR8943022 | — | — | 0.709 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.350 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.030 | Inavolisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |